Mediwound to present new escharex® data at leading wound care conferences

Presentations at whs and sawc to highlight escharex's mechanism of action, preclinical advantages over santyl ® , and new data in treating vlus and dfus findings reinforce the ongoing phase iii study in vlus and support the planned dfu trial strategy yavne, israel, april 28, 2025 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster presentations—at two of the world's premier wound care conferences: the wound healing society (whs) and the symposium on advanced wound care (sawc) spring 2025, taking place april 30–may 3 in grapevine, texas.
MDWD Ratings Summary
MDWD Quant Ranking